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The aim of the study was to investigate the time of onset and the duration of the bronchodilating effect of different 
doses of formoterol administered via Turbuhalerm in patients with moderate asthma. 
Thirty-one patients (five women) with a mean forced expiratory volume in 1 s (FEV,) of 1.97 & 0.54 1 and a mean 
reversibility of 31 f 14% of baseline were included in this double-blind, randomized, placebo-controlled and 
cross-over study. The patients inhaled single doses of placebo, i.e. 6, 12, 24, or 48,~g formoterol fumarate, on 5 
separate days. Serial measurements of specific airways conductance (SGAW) and FEV, were performed at regular 
time intervals for 12 h. 
The majority of the patients had at least a 50% increase in SGAW within 14 min after administration of all active 
treatments. The maximum increase in FEV, over placebo was dose-dependent: 12% (6 pug), 18% (12 pug), 19% (24 fig), 
and 26% (48 ,ug) (P<O.OOl). Twelve hours after administration of 6, 12, 24, and 48 pg formoterol, the mean increase 
in FEV, was still 7%, 15%, 18% and 27%, respectively, above the value following placebo. Headache was the most 
frequently reported adverse event in all treatments including placebo. After inhalation of 48pg, three patients 
experienced mild tremor lasting for less than 1 h; likewise, one patient experienced the same event for 3 h after 
placebo. 
Formoterol administered via Turbuhaler’R gave a rapid and dose-related bronchodilating effect lasting for 12 h 
and was well tolerated. 
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Introduction 
Formoterol is a long-acting inhaled &agonist used in the 
treatment of asthma. Most of the observations on the onset 
and duration of action of formoterol have been performed 
using a pressurized metered dose inhaler (pMD1) (14). 
Formoterol, administered via pMD1, has a rapid onset of 
action and a duration of bronchodilating and protective 
effect for up to 12 h (25). The minimal effective dose of 
formoterol inhaled from a pMD1 is situated at 12 pug (l-6). 
Dry powder inhalers are now being developed as an alter- 
native to chlorofluorocarbon-containing pMDIs (7-10). 
Turbuhale? is a multi-dose dry powder inhaler that 
has been shown to deliver approximately twice as much 
terbutaline and budesonide to the airways as a pMD1 
(10,ll). 
The aim of the present study was to investigate the onset 
and duration of the bronchodilating effect and the tolerabil- 
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ity of single doses of 6, 12, 24, and 48pg of formoterol 
fumarate (in the following referred to as formoterol) 
inhaled from Turbuhaler:! in patients with asthma. 
Patients and Methods 
PATIENTS 
Patients of either gender between 18 and 65 years of age 
were included. They all presented symptoms of asthma and 
exhibited a postbronchodilator increase in FEV, of at least 
15% of baseline, 15 min after inhalation of 1 mg terbutaline 
(BricanylcB Turbuhale@) or an equivalent drug. They were 
not allowed to enter the study if they had experienced an 
exacerbation of their asthma over the previous 4 weeks. 
Patients with chronic obstructive pulmonary disease 
(COPD) were excluded. Thirty-one Caucasian patients (five 
women), with a mean age of 50 f 12 years participated in 
the study. They exhibited a mean FEV, of 1.97 & 0.54 1 
(57 & 12% of predicted value) at study entry. Their mean 
reversibility of FEV, was 31 4 14% of baseline. The revers- 
ibility was less than 20% of baseline in five patients at 
inclusion; a postbronchodilator increase in FEV, ranging 
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between 20% and 40% of baseline had been documented in 
these patients on previous occasions. 
All patients used inhaled &-agonists ‘when needed’, 27 of 
them were on inhaled steroids prior to enrolment and 
continued the same treatment throughout the study. In 
addition, 10 patients used theophylline, three used anti- 
cholinergics and one patient used oral &agonists prior to 
and throughout the study. Twenty-three patients were 
ex-smokers and four had never smoked. Two patients 
smoked three cigarettes a day, two others four and five 
cigarettes a day. Seven patients were enrolled at a centre in 
Belgium and 24 patients at another centre in Norway. 
Prior to each study day, the patients discontinued inhaled 
short-acting &agonists for 8 h, oral &agonists for 12 h, 
anticholinergics for 24 h, and slow release theophyllines for 
48 h. Disodium cromoglycate, oral, inhaled, and nasal 
corticosteroids were permitted during the study, provided 
that the doses were kept constant during 4 weeks prior to, 
and throughout the study. 
STUDY DESIGN 
The study was randomized, cross-over, placebo-controlled, 
and double-blind. The study consisted of one screening 
visit, 5 study days separated by a 4-day wash-out period 
and a safety follow-up visit. On the 5 study days, each 
patient inhaled either placebo or one of the following single 
doses of formoterol via Turbuhaler? 6, 12, 24, and 48pg. 
These doses correspond to 4.5, 9, 18 and 36pg formoterol 
delivered from the mouthpiece of the inhaler (on file). Prior 
to the inhalation of the study drug, the patients practised 
their inhalation technique with a Vitalograph MDI- 
Compact providing them visual feed-back, until they were 
able to generate a peak inspiratory flow of at last 
60 1 min - ’ within 1 s. 
The study was approved by the National Health 
Authorities in Belgium and Norway and the local ethics 
committees. The patients gave their informed consent 
before enrolment in the study. 
ONSET AND DURATION OF ACTION 
A pulmonary function test was performed before inhalation 
of the study drug. Baseline FEV, measured on each of the 
5 study days has to be within 12% of the FEV, measured at 
the entry visit to ensure that they remained in a stable 
condition throughout the study. If not, they were asked to 
come back on another day. 
For determination of onset of action, body plethysmo- 
graphic measurements of specific airway conductance 
(SGAW) were made 1, 4, 7, 10, and 15 min after inhalation 
of the drug under investigation, using a constant volume 
body plethysmography (Masterlab, version 2.16, Jaeger, 
Wtirzburg, Germany). Treatment efficacy and duration of 
action were assessed using serial measurements of FEV, 
and SGAW, 30 min after inhalation of the study drug and 
hourly for 12 h. The best of three FEV, measurements, 
recorded by an Expirograph Godart at the Belgian clinic 
and by a Vitalograph MDI-Compact at the Norwegian 
clinic, were used. 
EXTRA-PULMONARY EFFECTS 
Pulse rate and blood pressure were measured in a sitting 
position before inhalation of the study drug, 30 min after, 
and hourly for 12 h on each study day. Tremor and other 
adverse effects were assessed by asking the patients stand- 
ardized questions before inhalation of the study drug, and 
15, 30 min, and 3, 6, and 12 h after inhalation. Blood 
samples for routine laboratory assessments (clinical chem- 
istry and haemotology) were obtained at entry and 
follow-up visits. 
STATISTICAL METHODS 
Using pairwise comparisons and assuming a standard 
deviation of about 30%, it was estimated that including 25 
patients would give an 80% probability of detecting a 
difference of at least 18% between treatments at a 5% level 
of significance. 
The statistical analysis was done on the maximal value of 
FEV, and SGAW. It was also done on the last FEV, value 
measured. The main principle of testing was that if the 
treatment had a statistically significant effect (PcO.05) 
according to Page’s test, the following analysis would 
proceed using pairwise comparisons based on an analysis of 
variance (ANOVA). The model was an additive one with 
the factors patient, period and treatment (no interactions). 
The adjusted means for treatments were compared as 
quotients and Fieller confidence limits (12) were computed. 
The time of onset of action was defined as the first time at 
which the patient had at least a 50% increase in SGAW over 
the baseline value. To find the lowest effective dose of 
formoterol, all doses were compared with placebo. The 
difference in adjusted means between placebo and active 
treatments was reported as the change from baseline. The 
maximal effective dose was established by pairwise com- 
parison between 48pg and the other doses, starting with 
24pg until a significant difference (PcO.05) was encoun- 
tered. A statistically significant difference between 48 and 
24,~~g would indicate that a plateau had not been reached 
and additional effect could be gained by giving even 
higher doses. 
Results 
ONSET AND DURATION OF ACTION 
All doses of formoterol caused a rapid, dose-dependent 
increase in SGAW, which reached statistical significance 
after 1 min compared with placebo (Fig. 1). At that time 
point, the mean increase in SGAW was already 24, 35, 54, 
and 94% from baseline after inhalation of 6, 12, 24, and 
48,~~g, respectively (P<O.OOOl). The highest dose, 48,~~g, 
caused a statistically significantly larger increase in SGAW 
than did 24pg (P=O.O025). Four minutes after inhalation 
of the 6 and 12,~~g dose, the mean increase in SGAW had 
exceeded 50% of baseline (Fig. 1). 
The fraction of patients exhibiting an increase of more 
than 50% of baseline (SGAW (Fig. 2) was 17%, 42%, 61% 
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and 92% at 1 min, and 57%, 67%, 87% and 96% 4 min after 
inhalation of 6, 12, 24, and 48,~g formoterol, respectively. 
With the 6 fig dose, at least 70% of the patients experienced 
a 50% increase in SGAW, 15 min and 30 min after inhala- 
tion of the drug (Fig. 2). The SGAW was almost unchanged 
after placebo. 
The mean baseline values ( f SD) for FEV, on the 5 study 
days were 1.84 & 0.57 1 (placebo), 1.77 k 0.47 1 (6 ,ug), 
1.87 f 0.59 1 (12,ug), 1.78 f 0.49 1 (24pg), and 1.87 f 0.58 1 
(48,~g). The deviation in baseline on the 5 study days was 
not statistically significant, and the within-patient variation 
in FEV, was 0.18 1 (CV=lO.l%), indicating that patients 
were in fairly stable condition. 
The maximum increase in FEV, (Fig. 3) was observed 
between 2 and 3 h after inhalation (6pg: 175 * 150 min; 
12pg: 164* 137 min; 24pg: 184+ 146min, and 48yg: 
226 f 191 min). The maximum increase in SGAW was 
observed at approximately the same time points. The 
maximum increase in FEV, was statistically significantly 
higher for all formoterol doses as compared with placebo 
(P<O.OOl) (Fig. 3). The 48,~g dose resulted in a maximum 
FEV, value of 2.65 f 0.69 1, which was statistically signifi- 
cantly higher (PcO.05) than the maximal values obtained 
after the administration of 24,ug (2.51 f 0.63 l), 12pg 
(2.48 f 0.70 1), 6 fig (2.32 f 0.70 l), and placebo (2.10 * 
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0.66 1). The lowest dose (6 pg) gave statistically significantly 
higher maximal FEV, values as compared with placebo 
(PO.05). Similarly, maximal SGAW after all doses of 
formoterol were statistically significantly higher than after 
placebo (BO.001). However, the maximal increase in 
SGAW after 48pg did not show a statistically significant 
difference, when compared to 24 or 12,~g (Fig. 4), but was 
significantly higher than the 6pg dose (P<O.OOl). 
The mean (95% CI) increases in FEV,, measured 12 h 
after administration of 6, 12, 24, and 48,~g, and expressed 
as a percentage over placebo FEV,, were 7% (O-15%), 15% 
(8-23%), 18% (1 l-27%), and 27% (19-36%), respectively. A 
substantial proportion of the patients remained 15% above 
their baseline FEV, after 12 h: 45% and 55% after 
inhalation of 24 and 48,~~g, respectively, and 20% after 
inhalation of 6 and 12,~g. An improvement in SGAW of 
50% of more was present in 17%, 33%, 57%, and 58% of 
the patients, 12 h after the 6, 12, 24, and 48,ug dose, 
respectively. 
Seven of the 31 patients discontinued their participation 
in the study procedures before the end of the study day 
because of asthma symptoms after placebo treatment. Four 
patients interrupted the study day prematurely after the 
6pg dose, two patients after the 12,~g dose, and one after 
inhalation of 48 pg formoterol. 
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EXTRA-PULMONARY EFFECTS 
Three patients experienced mild tremor. The longest dura- 
tion of tremor was reported after using placebo (one 
patient, 3 h). The same patient had tremor, which lasted for 
only 1 h, after 48,~g of formoterol. Two other patients 
experienced mild tremor after 48 pug formoterol, lasting for 
20 min and 1 h, respectively. No clinically relevant effect of 
the different doses of formoterol was detectable on mean 
and maximal pulse rate or blood pressure values. Mild or 
moderate headache was the most frequent adverse event. 
The number of patients suffering from headache was almost 
the same for all treatments, i.e. three after placebo, three 
after 6,~g, one after 12,~g, four after 24 pg, and three after 
48,~g of formoterol. Hence, a drug or dose-related effect 
could not be detected. Clinically relevant changes in the 
haematology and clinical chemistry variables were not 
observed. 
Discussion 
The present study demonstrates that single doses of 6, 12, 
24 and 48 pg formoterol inhaled from Turbuhaler ” 
resulted in a dose-related bronchodilating effect with a 
rapid onset and long duration of action. Although the 
bronchodilating effect decreased over time, the increase in 
FEV, remained statistically significant throughout the 
study as compared with placebo. Even after 12 h, the 
difference in FEV, between a 6pg formoterol dose and 
placebo reached statistical significance. Discontinuation of 
the study day occurred only after placebo or the two lowest 
doses in a few patients. 
The present findings are in line with earlier reports on the 
bronchodilating properties of inhaled formoterol. A similar 
rapid onset of effect on SGAW has been observed after 
single doses of formoterol inhaled from a pMD1 and other 
dry powder inhalers (2,3,6,7,13,14). As in other trials, the 
maximum effect was observed 2 to 3 h after inhalation 
(3,7,14) and the bronchodilating effect lasted for 12 h or 
more (3,8,14,15). As may be expected, a doseeresponse 
relationship was clearly present for most of the efficacy 
variables, such as maximum effect, onset time, and the time 
course of the FEV, and SGAW. This is in line with 
previously reported data (3,8,9). 
The current data indicate that 6,~g formoterol via 
Turbuhaler’” is an effective treatment. It caused a marked 
improvement in SGAW in more than 50% of the patients 
4 min after administration. Admittedly, the FEV, values 
had returned to baseline after 12 h (Fig. 3). Comparing the 
bronchodilating effect of the 6pg dose with placebo may, 
however, give us a better evaluation of the efficacy of this 
dose, as the time course of the FEV, after placebo reflects 
the diurnal variation in FEV,. Although the difference in 
FEV, between placebo and 6pg formoterol was small after 
12 h (Fig. 3), and caused some patients to ask for rescue 
medication, the observed 7% increase might be of clinical 
relevance in a number of patients. Indeed, in a recently 
published study, which included asthmatic patients with 
comparable baseline FEV, and reversibility to our patient 
population, it was shown that maintenance therapy with 
formoterol 6pg b.i.d. via Turbuhaler” was the lowest 
effective dose to increase the morning peak expiratory flow 
up to 12 h after dosing, decrease day-time and night-time 
asthma and reduce the use of rescue medication (16). 
Moreover, in a 3-month study, 6pg formoterol b.i.d. was 
more efficacious in improving peak expiratory flow and 
offered better asthma control than terbutaline 500 pg q.i.d. 
(17). Finally, it has been pointed out that 5Opg salmeterol 
inhaled via Diskhaler appeared to be as potent as 9,~g 
formoterol inhaled via Turbuhaler in patients with 
asthma (18). 
In conclusion, we have demonstrated that single doses 
of 648 pug of formoterol administered via Turbuhaler ” in 
patients with mild to moderate asthma produced a dose- 
related bronchodilating effect, with an onset of action 
within l-4 min and a 12-h effect duration. The adverse 
events of formoterol inhaled from the Turbuhaler ” were 
minimal, of mild intensity, and typical for &-agonists ( 19). 
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